Revvity TCP, -, 250 µCi

TCP acts as an antagonist at N-methyl-D-aspartate receptor (NMDA receptors), and is a dissociative anesthetic drug with hallucinogenic effects.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET886:

1. Z. Kawakami, H. Kanno, T. Ueki, K. Terawaki, M. Tabuchi, Y. Ikarashi, Y. Kase, Neuroprotective effects of yokukansan, a traditional japanese medicine, on glutamate-mediated excitotoxicity in cultured cells, Neuroscience, Volume 159, Issue 4, 2009, Pages 1397-1407.
2. Matthew A. Sills, Graham Fagg, Mario Pozza, Christof Angst, Derek E. Brundish, Stephen D. Hurt, E. Jay Wilusz, Michael Williams, [3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain, European Journal of Pharmacology, Volume 192, Issue 1, 1991, Pages 19-24.